- Price
- $55.07
- Day
- +1.06%
- Mkt Cap
- $9.15B
- 52W Range
- $40.03 – $86.74
- Volume
- 2.47M
- Beta
- 0.36
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. (“Ionis” or the “Company”) (NASDAQ: IONS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read full article
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) Director Michael Hayden purchased 15,000 shares of Ionis Pharmaceuticals stock in a transaction dated Thursday, July 30th. The shares were acquired at an average cost of $53.38 per share, for a total transaction of $800,700.00. Following the transaction, the director directly owned 19,000 shares of the company's
Read full article
20,000 shares were purchased for a total value of ~$1.1 million across multiple execution windows. The acquisition increased the director's total direct and indirect equity holdings by 34%.
Read full article
Ionis beats Q2 revenues and earnings estimates as commercial growth offsets tough comparisons, while reaffirming its 2026 outlook.
Read full article
NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read full article
Ionis Pharmaceuticals, Inc. (IONS) Q2 2026 Earnings Call Transcript
Read full article
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read full article
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.89. This compares to earnings of $0.86 per share a year ago.
Read full article
Ionis Pharmaceuticals NASDAQ: IONS reported second-quarter revenue growth driven by commercial products and partnered research programs, while highlighting the recent U.S. approval and early launch progress for TRYNGOLZA in severe hypertriglyceridemia.
Read full article
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the second quarter ended June 30, 2026. “With the approval of TRYNGOLZA in late June, Ionis is bringing the first and only treatment to reduce triglycerides and acute pancreatitis to people living with severe hypertriglyceridemia. We are encouraged by the early launch momentum and look forward to accelerating growth from TRYNGOLZA and our ot.
Read full article
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Frank Bennett, Ph.D., executive vice president and chief scientific officer, will retire effective February 2027.“As a founding scientist, Frank has been instrumental in shaping Ionis and advancing the entire field of RNA-targeted medicines,” said Brett P. Monia, Ph.D., chief executive officer, Ionis. “Frank's profound contributions include pioneering the use of antisense medicines in neurological.
Read full article
SAN FRANCISCO, July 28, 2026 (GLOBE NEWSWIRE) -- Investors in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) saw the price of their shares plunge $20.19 (-23%) on July 9, 2026 after the commercial stage biotech company and its partner (AstraZeneca) announced that a late-stage trial for an experimental heart disease therapy did not meet its target. The surprise result and severe market reaction have prompted national shareholders' rights firm Hagens Berman to open an investigation into whether Ionis was sufficiently transparent about the trial's data and design and, if not, whether the company may have violated the federal securities laws.
Read full article